Which has stronger earnings & valuation, LIVN or AORT?

Artivion has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.43B 2.99 -$242.47M $1.95 40.07 Artivion $441.33M 2.89 $9.77M $0.24 109.43

Is LIVN or AORT more profitable?

LivaNova has a net margin of 7.48% compared to Artivion's net margin of 2.55%. LivaNova's return on equity of 16.48% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Artivion 2.55% 7.15% 3.63%

Does the media refer more to LIVN or AORT?

In the previous week, LivaNova had 12 more articles in the media than Artivion. MarketBeat recorded 18 mentions for LivaNova and 6 mentions for Artivion. Artivion's average media sentiment score of 1.03 beat LivaNova's score of 1.03 indicating that Artivion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artivion 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, AORT or ITGR?

Integer has higher revenue and earnings than Artivion. Integer is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.89 $9.77M $0.24 109.43 Integer $1.85B 2.29 $102.81M $4.01 31.15

Is AORT or ITGR more profitable?

Integer has a net margin of 6.97% compared to Artivion's net margin of 2.55%. Integer's return on equity of 12.77% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Artivion 2.55% 7.15% 3.63% Integer 6.97% 12.77% 6.48%

Does the media prefer AORT or ITGR?

In the previous week, Integer had 29 more articles in the media than Artivion. MarketBeat recorded 35 mentions for Integer and 6 mentions for Artivion. Artivion's average media sentiment score of 1.03 beat Integer's score of 0.63 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integer 17 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, AORT or HAE?

Haemonetics has higher revenue and earnings than Artivion. Haemonetics is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.89 $9.77M $0.24 109.43 Haemonetics $1.33B 2.86 $97.31M $2.02 41.49

Is AORT or HAE more profitable?

Haemonetics has a net margin of 7.29% compared to Artivion's net margin of 2.55%. Haemonetics' return on equity of 27.30% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Artivion 2.55% 7.15% 3.63% Haemonetics 7.29% 27.30% 9.59%

Does the media prefer AORT or HAE?

In the previous week, Haemonetics had 5 more articles in the media than Artivion. MarketBeat recorded 11 mentions for Haemonetics and 6 mentions for Artivion. Artivion's average media sentiment score of 1.03 beat Haemonetics' score of 0.95 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AORT or IRTC?

In the previous week, Artivion had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Artivion and 5 mentions for iRhythm Technologies. Artivion's average media sentiment score of 1.03 beat iRhythm Technologies' score of 0.93 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, AORT or ESTA?

Artivion has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.89 $9.77M $0.24 109.43 Establishment Labs $211.08M 12.72 -$51.06M -$1.49 N/A

Does the media prefer AORT or ESTA?

In the previous week, Artivion had 1 more articles in the media than Establishment Labs. MarketBeat recorded 6 mentions for Artivion and 5 mentions for Establishment Labs. Artivion's average media sentiment score of 1.03 beat Establishment Labs' score of 0.53 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Live Earnings Conference Call: Artivion will host a live Q2 2026 earnings call on August 6, 2026 at 4:30PM ET. Get details.

Artivion (AORT) Competitors

$26.26 -0.64 (-2.37%)

Closing price 08/5/2026 03:59 PM Eastern

Extended Trading

$26.08 -0.18 (-0.69%)

As of 04:26 AM Eastern

Compare

AORT vs. LIVN, ITGR, HAE, IRTC, and ESTA

Should you buy Artivion stock or one of its competitors? MarketBeat compares Artivion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artivion include LivaNova (LIVN), Integer (ITGR), Haemonetics (HAE), iRhythm Technologies (IRTC), and Establishment Labs (ESTA). These companies are all part of the "healthcare equipment" industry.

How does Artivion compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Artivion (NYSE:AORT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

LivaNova currently has a consensus price target of $83.50, suggesting a potential upside of 6.86%. Artivion has a consensus price target of $44.17, suggesting a potential upside of 68.18%. Given Artivion's stronger consensus rating and higher probable upside, analysts plainly believe Artivion is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

97.6% of LivaNova shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 6.3% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, LivaNova had 12 more articles in the media than Artivion. MarketBeat recorded 18 mentions for LivaNova and 6 mentions for Artivion. Artivion's average media sentiment score of 1.03 beat LivaNova's score of 1.03 indicating that Artivion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artivion has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.43B	2.99	-$242.47M	$1.95	40.07
Artivion	$441.33M	2.89	$9.77M	$0.24	109.43

LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Artivion has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

LivaNova has a net margin of 7.48% compared to Artivion's net margin of 2.55%. LivaNova's return on equity of 16.48% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Artivion	2.55%	7.15%	3.63%

Summary

LivaNova beats Artivion on 9 of the 17 factors compared between the two stocks.

How does Artivion compare to Integer?

Artivion (NYSE:AORT) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Integer has higher revenue and earnings than Artivion. Integer is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.89	$9.77M	$0.24	109.43
Integer	$1.85B	2.29	$102.81M	$4.01	31.15

In the previous week, Integer had 29 more articles in the media than Artivion. MarketBeat recorded 35 mentions for Integer and 6 mentions for Artivion. Artivion's average media sentiment score of 1.03 beat Integer's score of 0.63 indicating that Artivion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integer	17 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Artivion has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Integer has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Artivion currently has a consensus target price of $44.17, suggesting a potential upside of 68.18%. Integer has a consensus target price of $109.86, suggesting a potential downside of 12.06%. Given Artivion's stronger consensus rating and higher probable upside, equities research analysts plainly believe Artivion is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

86.4% of Artivion shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Integer has a net margin of 6.97% compared to Artivion's net margin of 2.55%. Integer's return on equity of 12.77% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
Integer	6.97%	12.77%	6.48%

Summary

Artivion and Integer tied by winning 8 of the 16 factors compared between the two stocks.

How does Artivion compare to Haemonetics?

Artivion (NYSE:AORT) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Artivion has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

In the previous week, Haemonetics had 5 more articles in the media than Artivion. MarketBeat recorded 11 mentions for Haemonetics and 6 mentions for Artivion. Artivion's average media sentiment score of 1.03 beat Haemonetics' score of 0.95 indicating that Artivion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artivion currently has a consensus price target of $44.17, suggesting a potential upside of 68.18%. Haemonetics has a consensus price target of $78.89, suggesting a potential downside of 5.86%. Given Artivion's higher possible upside, equities analysts plainly believe Artivion is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Haemonetics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82

Haemonetics has higher revenue and earnings than Artivion. Haemonetics is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.89	$9.77M	$0.24	109.43
Haemonetics	$1.33B	2.86	$97.31M	$2.02	41.49

86.4% of Artivion shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 6.3% of Artivion shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Haemonetics has a net margin of 7.29% compared to Artivion's net margin of 2.55%. Haemonetics' return on equity of 27.30% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
Haemonetics	7.29%	27.30%	9.59%

Summary

Haemonetics beats Artivion on 10 of the 16 factors compared between the two stocks.

How does Artivion compare to iRhythm Technologies?

Artivion (NYSE:AORT) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Artivion has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Artivion has a net margin of 2.55% compared to iRhythm Technologies' net margin of -3.53%. Artivion's return on equity of 7.15% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

Artivion has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.89	$9.77M	$0.24	109.43
iRhythm Technologies	$747.14M	5.48	-$44.55M	-$0.86	N/A

Artivion presently has a consensus price target of $44.17, indicating a potential upside of 68.18%. iRhythm Technologies has a consensus price target of $184.71, indicating a potential upside of 48.36%. Given Artivion's higher possible upside, research analysts plainly believe Artivion is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

86.4% of Artivion shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Artivion had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Artivion and 5 mentions for iRhythm Technologies. Artivion's average media sentiment score of 1.03 beat iRhythm Technologies' score of 0.93 indicating that Artivion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Artivion beats iRhythm Technologies on 11 of the 17 factors compared between the two stocks.

How does Artivion compare to Establishment Labs?

Artivion (NYSE:AORT) and Establishment Labs (NASDAQ:ESTA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Artivion had 1 more articles in the media than Establishment Labs. MarketBeat recorded 6 mentions for Artivion and 5 mentions for Establishment Labs. Artivion's average media sentiment score of 1.03 beat Establishment Labs' score of 0.53 indicating that Artivion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artivion has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.89	$9.77M	$0.24	109.43
Establishment Labs	$211.08M	12.72	-$51.06M	-$1.49	N/A

Artivion has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Artivion currently has a consensus target price of $44.17, indicating a potential upside of 68.18%. Establishment Labs has a consensus target price of $93.75, indicating a potential upside of 2.74%. Given Artivion's stronger consensus rating and higher possible upside, research analysts clearly believe Artivion is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Artivion has a net margin of 2.55% compared to Establishment Labs' net margin of -19.05%. Artivion's return on equity of 7.15% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
Establishment Labs	-19.05%	-218.77%	-12.31%

86.4% of Artivion shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Artivion beats Establishment Labs on 13 of the 15 factors compared between the two stocks.

Get Artivion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AORT vs. The Competition

Export

Metric	Artivion	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.31B	$5.80B	$6.86B	$24.09B
Dividend Yield	N/A	1.78%	2.60%	3.70%
P/E Ratio	109.43	23.50	280.40	32.26
Price / Sales	2.89	58.73	562.13	20.44
Price / Cash	24.41	32.67	71.79	32.38
Price / Book	2.78	6.12	12.94	6.92
Net Income	$9.77M	$151.74M	$3.49B	$1.07B
7 Day Performance	-5.10%	3.51%	2.42%	2.10%
1 Month Performance	6.13%	-1.62%	-2.87%	1.67%
1 Year Performance	-18.71%	8.95%	75.29%	19.52%

Artivion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AORT Artivion	4.3504 of 5 stars	$26.26 -2.4%	$44.17 +68.2%	-18.2%	$1.31B	$441.33M	109.43	1,800
LIVN LivaNova	2.9731 of 5 stars	$82.46 +2.9%	$81.38 -1.3%	+83.4%	$4.40B	$1.39B	42.29	3,300	Trending News Earnings Report Analyst Forecast
ITGR Integer	2.0385 of 5 stars	$124.45 +2.7%	$103.71 -16.7%	+16.1%	$4.12B	$1.85B	31.03	11,000	Earnings Report Analyst Downgrade High Trading Volume
HAE Haemonetics	2.9105 of 5 stars	$86.79 +1.5%	$78.89 -9.1%	+10.1%	$3.89B	$1.33B	42.96	3,009
IRTC iRhythm Technologies	4.2569 of 5 stars	$124.66 +6.4%	$184.71 +48.2%	-22.4%	$3.85B	$747.14M	N/A	2,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AORT) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artivion (AORT) Competitors

AORT vs. LIVN, ITGR, HAE, IRTC, and ESTA

How does Artivion compare to LivaNova?

Summary

How does Artivion compare to Integer?

Summary

How does Artivion compare to Haemonetics?

Summary

How does Artivion compare to iRhythm Technologies?

Summary

How does Artivion compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artivion (AORT) Competitors

AORT vs. LIVN, ITGR, HAE, IRTC, and ESTA

How does Artivion compare to LivaNova?

Do analysts recommend LIVN or AORT?

Do insiders and institutionals believe in LIVN or AORT?

Does the media refer more to LIVN or AORT?

Which has stronger earnings & valuation, LIVN or AORT?

Which has more risk & volatility, LIVN or AORT?

Is LIVN or AORT more profitable?

Summary

How does Artivion compare to Integer?

Which has stronger earnings & valuation, AORT or ITGR?

Does the media prefer AORT or ITGR?

Which has more volatility & risk, AORT or ITGR?

Do analysts recommend AORT or ITGR?

Do insiders & institutionals hold more shares of AORT or ITGR?

Is AORT or ITGR more profitable?

Summary

How does Artivion compare to Haemonetics?

Which has more volatility & risk, AORT or HAE?

Does the media prefer AORT or HAE?

Do analysts rate AORT or HAE?

Which has stronger valuation and earnings, AORT or HAE?

Do insiders and institutionals hold more shares of AORT or HAE?

Is AORT or HAE more profitable?

Summary

How does Artivion compare to iRhythm Technologies?

Which has more volatility and risk, AORT or IRTC?

Is AORT or IRTC more profitable?

Which has higher valuation and earnings, AORT or IRTC?

Do analysts rate AORT or IRTC?

Do insiders & institutionals believe in AORT or IRTC?

Does the media prefer AORT or IRTC?

Summary

How does Artivion compare to Establishment Labs?

Does the media prefer AORT or ESTA?

Which has preferable earnings & valuation, AORT or ESTA?

Which has more risk & volatility, AORT or ESTA?

Do analysts rate AORT or ESTA?

Is AORT or ESTA more profitable?

Do insiders and institutionals believe in AORT or ESTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools